Exacerbation frequency and clinical outcomes in adult p

Thorax

66, 680-685

DOI: 10.1136/thx.2011.161117

Citation Report

#	Article	IF	Citations
1	Sex steroid receptors in human lung diseases. Journal of Steroid Biochemistry and Molecular Biology, 2011, 127, 216-222.	1.2	37
2	Cystic fibrosis papers of the year 2010-2011. Journal of the Royal Society of Medicine, 2012, 105, 30-35.	1.1	1
3	Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. European Respiratory Journal, 2012, 40, 61-66.	3.1	201
4	The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of Exacerbations. PLoS ONE, 2012, 7, e45001.	1.1	320
5	Iron Homeostasis during Cystic Fibrosis Pulmonary Exacerbation. Clinical and Translational Science, 2012, 5, 368-373.	1.5	29
6	Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2012, 6, 363-373.	1.0	7
7	Viral infections trigger exacerbations of cystic fibrosis in adults and children: Figure 1â€“. European Respiratory Journal, 2012, 40, 510-512.	3.1	67
8	I have taken my umbrella, so of course it does not rain: Figure 1. Thorax, 2012, 67, 88-89.	2.7	31
9	Houttuynia cordata inhibits lipopolysaccharide-induced rapid pulmonary fibrosis by up-regulating IFN-Î³ and inhibiting the TGF-Î²1/Smad pathway. International Immunopharmacology, 2012, 13, 331-340.	1.7	35
10	Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. The Cochrane Library, 2012, 12, CD008319.	1.5	21
11	Recent Advances in Cystic Fibrosis. Clinics in Chest Medicine, 2012, 33, 307-328.	0.8	20
12	Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation. Dermato-Endocrinology, 2012, 4, 191-197.	1.9	74
13	Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study. PLoS ONE, 2012, 7, e36077.	1.1	72
15	The Prognosis of Cystic Fibrosis - A Clinician's Perspective. , 2012, , .		1
16	Impact of exacerbations of cystic fibrosis on muscle strength. Respiratory Research, 2013, 14, 46.	1.4	37
17	A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatric Pulmonology, 2013, 48, 954-961.	1.0	13
18	Cystic Fibrosis Papers of the Year 2012. Paediatric Respiratory Reviews, 2013, 14, 28-30.	1.2	3
19	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials, 2013, 36, 99-105.	0.8	8

#	Article	IF	Citations
20	Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 688-699.	0.3	21
21	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 666-673.	1.0	99
22	New agents to treat lung infection in cystic fibrosis: a big enough leap?. Future Medicinal Chemistry, 2013, 5, 117-120.	1.1	0
23	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5â€...years of age. Thorax, 2013, 68, 643-651.	2.7	83
24	Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. European Respiratory Journal, 2013, 41, 571-577.	3.1	45
25	Effect of residential proximity to major roadways on cystic fibrosis exacerbations. International Journal of Environmental Health Research, 2013, 23, 119-131.	1.3	19
26	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric Pulmonology, 2013, 48, 525-537.	1.0	27
27	The CF-ABLE Score. Chest, 2013, 143, 1358-1364.	0.4	33
28	Ozone Is Associated With an Increased Risk of Respiratory Exacerbations in Patients With Cystic Fibrosis. Chest, 2013, 144, 1186-1192.	0.4	41
29	Peripheral Monocytes Derived from Patients with Cystic Fibrosis and Healthy Donors Secrete NGAL in Response to Pseudomonas aeruginosa Infection. Journal of Investigative Medicine, 2013, 61, 1018-1025.	0.7	19
30	Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis. BMC Pulmonary Medicine, 2014, 14, 150.	0.8	16
31	Gender Differences in Outcomes of Patients with Cystic Fibrosis. Journal of Women's Health, 2014, 23, 1012-1020.	1.5	138
32	Year in review 2013: paediatric and adult clinical studies. Thorax, 2014, 69, 309-311.	2.7	2
33	Vitamin D Deficiency Is Associated with Pulmonary Exacerbations in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2014, 11, 198-204.	1.5	63
34	Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men. Pediatric Pulmonology, 2014, 49, 28-35.	1.0	41
35	Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax, 2014, 69, 247-253.	2.7	107
36	Aerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis. Pediatric Pulmonology, 2014, 49, 641-649.	1.0	67
37	What is the importance of classifyingAspergillusdisease in cystic fibrosis patients?. Expert Review of Respiratory Medicine, 2014, 8, 389-392.	1.0	21

#	Article	IF	Citations
38	Early Respiratory Infection Is Associated with Reduced Spirometry in Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1111-1116.	2.5	142
39	Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF). Journal of Cystic Fibrosis, 2014, 13, 692-698.	0.3	54
41	Survival in Cystic Fibrosis: Trends, Clinical Factors, and Prediction Models. Pediatric, Allergy, Immunology, and Pulmonology, 2015, 28, 244-249.	0.3	4
42	Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Current Opinion in Infectious Diseases, 2015, 28, 547-556.	1.3	67
43	Respiratory tract exacerbations revisited: Ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. Pediatric Pulmonology, 2015, 50, S57-65.	1.0	29
44	Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. The Cochrane Library, 2015, , CD009730.	1.5	19
45	Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 151.	0.8	27
46	Variation in lung function is associated with worse clinical outcomes in cystic fibrosis. Jornal Brasileiro De Pneumologia, 2015, 41, 509-515.	0.4	8
47	A statistical model to predict one-year risk of death in patients with cystic fibrosis. Journal of Clinical Epidemiology, 2015, 68, 1336-1345.	2.4	65
48	Mucoviscidose. Revue Des Maladies Respiratoires Actualites, 2015, 7, S12-S22.	0.0	0
49	Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. Journal of Cystic Fibrosis, 2015, 14, 482-489.	0.3	30
50	A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. ISME Journal, 2015, 9, 1024-1038.	4.4	59
51	Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice. Expert Review of Respiratory Medicine, 2015, 9, 183-194.	1.0	14
52	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 755-762.	0.3	62
53	Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF-κB-Mediated Inflammation. Medical Principles and Practice, 2015, 24, 301-310.	1.1	12
54	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 763-769.	0.3	38
55	Rehabilitation in Patients with Chronic Respiratory Disease Other than Chronic Obstructive Pulmonary Disease: Exercise and Physical Activity Interventions in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. Respiration, 2015, 89, 181-189.	1.2	48
56	Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis. Journal of Pediatric Health Care, 2015, 29, 565-578.	0.6	10

#	Article	IF	Citations
57	Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric Respiratory Reviews, 2015, 16, 246-248.	1.2	5
58	A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. European Respiratory Journal, 2015, 45, 670-679.	3.1	154
59	Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionals. Journal of Cystic Fibrosis, 2015, 14, 90-96.	0.3	10
60	C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations. Journal of Pulmonary & Respiratory Medicine, 2016, 6, 1000375.	0.1	19
61	Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate normative adherence. Patient Preference and Adherence, 2016, 10, 887.	0.8	20
62	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238.	1.1	53
63	Recovery of baseline lung function after pulmonary exacerbation in children with primary ciliary dyskinesia. Pediatric Pulmonology, 2016, 51, 1362-1366.	1.0	31
64	Asthma attacks: should we nail our colours to the mast (cell)?. European Respiratory Journal, 2016, 48, 1261-1264.	3.1	2
65	Cystic Fibrosis-Related Diabetes with strict glycaemic control is not associated with frequent intravenous antibiotics use for pulmonary infections. Diabetes Research and Clinical Practice, 2016, 116, 230-236.	1.1	6
66	IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 372-379.	0.3	35
67	Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Journal of Medical Economics, 2016, 19, 845-851.	1.0	13
68	Cystic fibrosis. Lancet, The, 2016, 388, 2519-2531.	6.3	1,309
69	Pseudomonas aeruginosainfection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Review of Respiratory Medicine, 2016, 10, 685-697.	1.0	114
70	Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline. Annals of the American Thoracic Society, 2016, 13, 2174-2183.	1.5	8
71	Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 1221-1228.	1.0	5
72	Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study. Lancet Respiratory Medicine,the, 2016, 4, 636-645.	5.2	19
73	Advance care planning in adolescents with cystic fibrosis: A quality improvement project. Pediatric Pulmonology, 2016, 51, 1304-1310.	1.0	20
74	Ecological networking of cystic fibrosis lung infections. Npj Biofilms and Microbiomes, 2016, 2, 4.	2.9	77

#	Article	IF	Citations
75	Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes, 2016, 14, 63.	1.0	37
76	A longitudinal study characterising a large adult primary ciliary dyskinesia population. European Respiratory Journal, 2016, 48, 441-450.	3.1	101
77	Expiratory Flow Limitation for Monitoring Cystic Fibrosis. Ready for the Starting Gun?. Annals of the American Thoracic Society, 2016, 13, 770-771.	1.5	0
78	Optimising treatment of CF pulmonary exacerbation: a tough nut to crack. Thorax, 2016, 71, 101-102.	2.7	5
79	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. Antimicrobial Agents and Chemotherapy, 2016, 60, 2180-2184.	1.4	16
80	A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax, 2016, 71, 141-147.	2.7	40
81	Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax, 2016, 71, 223-229.	2.7	53
82	The diagnosis and management of respiratory viral infections in cystic fibrosis. Expert Review of Respiratory Medicine, 2017, 11, 221-227.	1.0	23
83	Six-Minute Walk Test Results Predict Risk of Hospitalization for Youths with Cystic Fibrosis: A 5-Year Follow-Up Study. Journal of Pediatrics, 2017, 182, 204-209.e1.	0.9	28
84	Early Lung Function Decline in Cystic Fibrosis. Can Registry Data Explain Divergent Phenotypes?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 407-409.	2.5	1
85	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. Journal of Cystic Fibrosis, 2017, 16, 600-606.	0.3	76
86	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 695-701.	0.3	4
87	The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Medicale, 2017, 46, e139-e164.	0.8	12
88	Effect of Anaerobiasis or Hypoxia on Pseudomonas aeruginosa Inhibition of Aspergillus fumigatus Biofilm. Archives of Microbiology, 2017, 199, 881-890.	1.0	21
89	Association between glucose intolerance and bacterial colonisation in an adult population with cystic fibrosis, emergence of Stenotrophomonas maltophilia. Journal of Cystic Fibrosis, 2017, 16, 418-424.	0.3	13
90	Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax, 2017, 72, 327-332.	2.7	58
91	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respiratory Medicine,the, 2017, 5, 107-118.	5.2	235
92	A first step to STOP cystic fibrosis exacerbations. Journal of Cystic Fibrosis, 2017, 16, 529-531.	0.3	7

#	Article	IF	Citations
93	CFâ€•related diabetes: Containing the metabolic miscreant of cystic fibrosis. Pediatric Pulmonology, 2017, 52, S37-S43.	1.0	43
94	Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine, 2017, 35, 5019-5026.	1.7	1
95	Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. New England Journal of Medicine, 2017, 377, 2013-2023.	13.9	625
96	A prospective pilot study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised controlled trial. BMC Pulmonary Medicine, 2017, 17, 22.	0.8	19
97	Microbiome in the pathogenesis of cystic fibrosis and lung transplant-related disease. Translational Research, 2017, 179, 84-96.	2.2	29
98	Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study. BMC Pulmonary Medicine, 2017, 17, 160.	0.8	5
99	Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 138.	0.8	11
100	Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013. Intractable and Rare Diseases Research, 2017, 6, 191-198.	0.3	24
101	A smartphone application for reporting symptoms in adults with cystic fibrosis: protocol of a randomised controlled trial. BMJ Open, 2018, 8, e021136.	0.8	6
102	The expression of Mirc1/Mir17â€“92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2018, 17, 454-461.	0.3	24
103	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials, 2018, 64, 35-40.	0.8	42
104	Pharmacological management of cystic fibrosis related diabetes. Expert Review of Clinical Pharmacology, 2018, 11, 185-191.	1.3	13
105	â€˜We canâ€™t diagnose asthma until <insert arbitrary age>â€™. Archives of Disease in Childhood, 2018, 103, 729-731.	1.0	10
106	Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of Aspergillus fumigatus Biofilm. Journal of Bacteriology, 2018, 200, .	1.0	99
107	Aspergillus Bronchitis in Patients with Cystic Fibrosis. Mycopathologia, 2018, 183, 61-69.	1.3	65
108	Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2018, 17, 333-340.	0.3	9
109	Daily spirometry in an acute exacerbation of adult cystic fibrosis patients. Chronic Respiratory Disease, 2018, 15, 258-264.	1.0	4
110	Fungal Pathogens in CF Airways: Leave or Treat?. Mycopathologia, 2018, 183, 119-137.	1.3	32

#	Article	IF	Citations
111	Niche partitioning of a pathogenic microbiome driven by chemical gradients. Science Advances, 2018, 4, eaau1908.	4.7	40
112	ASSOCIAÃ‡ÃƒO DO ESTADO NUTRICIONAL COM FUNÃ‡ÃƒO PULMONAR E MORBIDADE EM CRIANÃ‡AS E ADOLESCENTES COM FIBROSE CÃSTICA: COORTE DE 36 MESES. Revista Paulista De Pediatria, 2018, 36, 31-38.	0.4	8
113	Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Review of Respiratory Medicine, 2018, 12, 585-593.	1.0	17
114	Course of Illness after Viral Infection in Indian Children with Cystic Fibrosis. Journal of Tropical Pediatrics, 2019, 65, 176-182.	0.7	6
115	Adult patientsâ€™ experiences of symptom management during pulmonary exacerbations in cystic fibrosis: A thematic synthesis of qualitative research. Chronic Illness, 2019, 15, 245-263.	0.6	5
116	Long-Term Consequences of Childhood Respiratory Disease. , 2019, , 247-256.e4.		0
117	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. Journal of Cystic Fibrosis, 2019, 18, 94-101.	0.3	36
118	â€œThrust out of normalityâ€â€”How adults living with cystic fibrosis experience pulmonary exacerbations: A qualitative study. Journal of Clinical Nursing, 2019, 28, 190-200.	1.4	10
119	Elexacaftorâ€“Tezacaftorâ€“Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine, 2019, 381, 1809-1819.	13.9	1,231
120	Intermicrobial interaction: Aspergillus fumigatus siderophores protect against competition by Pseudomonas aeruginosa. PLoS ONE, 2019, 14, e0216085.	1.1	53
121	The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases. Antioxidants and Redox Signaling, 2019, 31, 954-993.	2.5	50
122	Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. Journal of Cystic Fibrosis, 2019, 18, 321-333.	0.3	154
123	Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Annals of the American Thoracic Society, 2019, 16, 853-860.	1.5	12
124	New insights into exogenous surfactant as a carrier of pulmonary therapeutics. Biochemical Pharmacology, 2019, 164, 64-73.	2.0	30
125	Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial. American Journal of Clinical Nutrition, 2019, 109, 544-553.	2.2	27
126	Adult Care in Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 857-868.	0.8	8
127	Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. Journal of Pediatrics, 2019, 215, 164-171.e2.	0.9	16
128	Cystic Fibrosis: Emerging Understanding and Therapies. Annual Review of Medicine, 2019, 70, 197-210.	5.0	39

#	Article	IF	Citations
129	Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. Journal of Cystic Fibrosis, 2020, 19, 114-118.	0.3	7
130	A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: Results of a randomised controlled trial. Journal of Cystic Fibrosis, 2020, 19, 271-276.	0.3	23
131	Real-Life Safety and Effectiveness of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	2.5	95
132	Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. Journal of Cystic Fibrosis, 2020, 19, 415-420.	0.3	15
133	Extracellular DNA in sputum is associated with pulmonary function and hospitalization in patients with cystic fibrosis. Respiratory Medicine, 2020, 172, 106144.	1.3	15
134	Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort. Annals of the American Thoracic Society, 2020, 17, 1384-1392.	1.5	19
135	Timing it right: the challenge of recipient selection for lung transplantation. Annals of Translational Medicine, 2020, 8, 408-408.	0.7	4
136	CFTR modulator therapies â€“ Effect on life expectancy in people with cystic fibrosis. Paediatric Respiratory Reviews, 2022, 42, 3-8.	1.2	26
137	Optimizing Exogenous Surfactant as a Pulmonary Delivery Vehicle for Chicken Cathelicidin-2. Scientific Reports, 2020, 10, 9392.	1.6	5
138	Review of Potential Pseudomonas Weaponry, Relevant to the Pseudomonasâ€“Aspergillus Interplay, for the Mycology Community. Journal of Fungi (Basel, Switzerland), 2020, 6, 81.	1.5	32
139	Procalcitonin Predicts the Severity of Cystic Fibrosis Pulmonary Exacerbations and Readmissions in Adult Patients: A Prospective Cohort Study. Journal of Investigative Medicine, 2020, 68, 856-863.	0.7	5
140	Complete versus Limited Endoscopic Sinus Surgery for Chronic Rhinosinusitis in Adults with Cystic Fibrosis. Otolaryngology - Head and Neck Surgery, 2020, 162, 572-580.	1.1	6
141	Enhancing care for individuals with advanced cystic fibrosis lung disease. Pediatric Pulmonology, 2021, 56, S69-S78.	1.0	0
142	Impulse oscillometry and spirometry measurements relative to personal best values at the time of acute exacerbations of cystic fibrosis in adults. Clinical Physiology and Functional Imaging, 2021, 41, 76-84.	0.5	2
143	Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 977-986.	2.5	34
144	Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations. Endocrinology, Diabetes and Metabolism, 2021, 4, e00208.	1.0	4
145	Under nonlimiting iron conditions pyocyanin is a major antifungal molecule, and differences between prototypic Pseudomonas aeruginosa strains. Medical Mycology, 2021, 59, 453-464.	0.3	16
146	Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses. Clinical Pharmacokinetics, 2021, 60, 447-470.	1.6	5

#	Article	IF	Citations
147	Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal. International Journal of Environmental Research and Public Health, 2021, 18, 1101.	1.2	8
148	Long-term safety and efficacy of tezacaftorâ€“ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	5.2	33
149	Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 157-165.	0.5	0
150	Early Interleukin-22 and Neutrophil Proteins Are Correlated to Future Lung Damage in Children With Cystic Fibrosis. Frontiers in Pediatrics, 2021, 9, 640184.	0.9	4
151	A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends. Scientific Reports, 2021, 11, 4897.	1.6	3
152	SPLUNC1: a novel marker of cystic fibrosis exacerbations. European Respiratory Journal, 2021, 58, 2000507.	3.1	20
153	Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2021, 20, 920-925.	0.3	10
154	Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting. Journal of Cystic Fibrosis, 2021, 20, 1035-1039.	0.3	7
155	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 1349-1379.	0.3	293
156	Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis, 2022, 21, 96-103.	0.3	2
157	Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians. BMJ Open Respiratory Research, 2021, 8, e000956.	1.2	4
158	Challenges Faced by Women with Cystic Fibrosis. Clinics in Chest Medicine, 2021, 42, 517-530.	0.8	9
159	Digital technology for early identification of exacerbations in people with cystic fibrosis. The Cochrane Library, 2021, 2021, .	1.5	1
160	Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1026-1034.	0.3	9
161	Indoor air pollution exposure is associated with greater morbidity in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, e129-e135.	0.3	7
162	A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1295-1305.	2.5	45
163	Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2022, 21, 562-573.	0.3	4
164	Lung Transplantation: Recipient Selection. , 2022, , 606-622.		0

#	Article	IF	Citations
165	Sex Differences in Cystic Fibrosis Across the Lifespan. Physiology in Health and Disease, 2021, , 145-168.	0.2	1
166	Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. The Cochrane Library, 2018, 2018, CD008319.	1.5	18
167	Pulmonary Exacerbations. Respiratory Medicine, 2020, , 181-198.	0.1	1
168	Novel intermicrobial molecular interaction: Pseudomonas aeruginosa Quinolone Signal (PQS) modulates Aspergillus fumigatus response to iron. Microbiology (United Kingdom), 2020, 166, 44-55.	0.7	33
169	Is the Improvement of CF Patients, Hospitalized for Pulmonary Exacerbation, Correlated to a Decrease in Bacterial Load?. PLoS ONE, 2013, 8, e79010.	1.1	28
170	Candidate Markers Associated with the Probability of Future Pulmonary Exacerbations in Cystic Fibrosis Patients. PLoS ONE, 2014, 9, e88567.	1.1	46
171	Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. PLoS ONE, 2015, 10, e0134692.	1.1	77
172	Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. PeerJ, 2016, 4, e2174.	0.9	45
173	The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF. Journal of Cystic Fibrosis, 2022, 21, 70-77.	0.3	13
174	Altered Pseudomonas Strategies to Inhibit Surface Aspergillus Colonies. Frontiers in Cellular and Infection Microbiology, 2021, 11, 734296.	1.8	7
175	Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation. Journal of Clinical Medicine, 2021, 10, 4884.	1.0	12
176	An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research, 2021, 9, 1-146.	0.4	6
177	SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	0
178	Exploring Associations Between Self-Compassion, Self-Criticism, Mental Health, and Quality of Life in Adults with Cystic Fibrosis: Informing Future Interventions. Journal of Clinical Psychology in Medical Settings, 2021, , 1.	0.8	7
179	Long-term oral antibiotic treatment: why, what, when and to whom?. , 0, , 185-205.		0
180	Cystic fibrosis: treatment and prevention of pulmonary exacerbations. , 0, , 167-180.		1
181	Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. Journal of Cystic Fibrosis, 2022, 21, 574-580.	0.3	8
182	The Effects of Aspergillus fumigatus Colonization on Lung Function in Patients with Cystic Fibrosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 944.	1.5	6

#	Article	IF	Citations
184	Static mucus impairs bacterial clearance and allows chronic infection withPseudomonas aeruginosain the cystic fibrosis rat. European Respiratory Journal, 2022, 60, 2101032.	3.1	10
185	Preliminary method for profiling volatile organic compounds in breath that correlate with pulmonary function and other clinical traits of subjects diagnosed with cystic fibrosis: a pilot study. Journal of Breath Research, 2022, 16, 027103.	1.5	9
186	Caregiver burden in cystic fibrosis: a systematic literature review. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662210864.	1.0	6
187	A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662110701.	1.0	7
188	Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Decreasing Severe Cystic Fibrosis-Related Exacerbations in Specialty Pharmacy Patients and Vulnerable Subgroups: A Retrospective, Pre-Post Study. SSRN Electronic Journal, 0, , .	0.4	0
189	Parenthood impacts short-term health outcomes in people with cystic fibrosis. Journal of Cystic Fibrosis, 2022, , .	0.3	8
190	Clinical Impact of Aspergillus fumigatus in Children with Cystic Fibrosis. Microorganisms, 2022, 10, 739.	1.6	1
191	Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respiratory Research, 2021, 8, e000998.	1.2	4
192	Development and Internal Validation of a Prognostic Model of the Probability of Death or Lung Transplantation Within 2 Years for Patients With Cystic Fibrosis and FEV1Ââ‰ 50%ÂPredicted. Chest, 2022, 162, 757-767.	0.4	4
193	VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected nonâ€“G551D-CFTR gating mutations. Journal of Cystic Fibrosis, 2023, 22, 124-131.	0.3	4
194	The Impact of Air Pollution on the Course of Cystic Fibrosis: A Review. Frontiers in Physiology, 2022, 13, .	1.3	3
195	Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study. Archivos De Bronconeumologia, 2022, , .	0.4	1
196	Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEV1, Lung Clearance Index and Peak Work Rate. Frontiers in Pediatrics, 0, 10, .	0.9	1
197	The Utility of Glucose Area Under the Curve from The Oral Glucose Tolerance Test as a Screening Tool for Cystic Fibrosis â€Related Diabetes. Pediatric Pulmonology, 0, , .	1.0	0
198	Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. The Cochrane Library, 2022, 2022, .	1.5	2
199	Antimicrobial Stewardship in Cystic Fibrosis. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S53-S61.	0.6	3
200	Mediation of the total effect of cystic fibrosisâ€related diabetes on mortality: A <scp>UK</scp> Cystic Fibrosis Registry cohort study. Diabetic Medicine, 2022, 39, .	1.2	3
201	Respiratory Viruses and Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 196-208.	0.8	1

#	Article	IF	Citations
202	Airway clearance therapy in the school environment: Retrospective analysis of a cohort of pediatric patients with cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 811-815.	0.3	0
203	The Lung Transplant Candidate, Indications, Timing, and Selection Criteria. Clinics in Chest Medicine, 2023, 44, 15-33.	0.8	0
204	The Clinical Association betweenAspergillus fumigatusand Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis. Annals of the American Thoracic Society, 2023, 20, 984-992.	1.5	4
205	Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis. Respiratory Care, 2023, 68, 620-627.	0.8	0
206	Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosisâ€"A Single-Centre Prospective Observational Study. Antibiotics, 2023, 12, 734.	1.5	0
207	Digital technology for early identification of exacerbations in people with cystic fibrosis. The Cochrane Library, 2023, 2023, .	1.5	3